Dicerna Pharmaceuticals has shared interim phase 1 data on its Roche-partnered hepatitis B drug RG6346. The trial linked RG6346 to reductions in hepatitis B surface antigen (HBsAg) that suggest the RNAi therapy can hold its own against rival candidates in development at Johnson & Johnson and Vir Biotechnology.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,